Title: Randomized, open label, multicentre phase III study of efficacy and safety in polycythermia versus subjects who are resilient to or intolerant of hydroxyurea: JAK inhibitor INC424 tablets versus best available care
Funder
Novartis Pharmaceuticals UK Ltd
Principal Investigator
Project Details
Net value award figure for Cardiff University: £3,795.00
Start date: 30/03/2011
End date: 31/03/2017
